

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

[gov.uk/mhra](https://www.gov.uk/mhra)

Decision Cover Letter

Decision of the licensing authority to:

accept change(s) to the agreed paediatric investigation plan (MHRA-100535-PIP01-22-M01)
MHRA-100535-PIP01-22-M02

Scope of the Application

Active Substance(s)

FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE

Condition(s)

Treatment of Asthma

Pharmaceutical Form(s)

Inhalation powder, pre-dispensed

Route(s) of Administration

INHALATION USE

Name / Corporate name of the PIP applicant

GlaxoSmithKline UK Limited

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, GlaxoSmithKline UK Limited submitted to the licensing authority on 04/10/2022 12:09 BST an application for a Modification

The procedure started on 09/03/2023 08:12 GMT

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to accept change(s) to the agreed paediatric investigation plan

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-100535-PIP01-22-M02

Of 24/03/2023 13:09 GMT

On the adopted decision for FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE (MHRA-100535-PIP01-22-M02) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan (including modification of a waiver or deferral included in that paediatric investigation plan)

This decision applies to a Modification for FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE, Inhalation powder, pre-dispensed , INHALATION USE .

This decision is addressed to GlaxoSmithKline UK Limited, 980 Great West Road, Brentford, UNITED KINGDOM, TW8 9GS

ANNEX I

1. Waiver

1.1 Condition:

Treatment of Asthma The waiver applies / applied to: Paediatric Subset(s): The paediatric population from birth to less than 5 years of age Pharmaceutical form(s): Inhalation powder, pre-dispensed Route(s) of administration: INHALATION USE Reason for granting waiver: on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible.

2. Paediatric Investigation Plan:

2.1 Condition(s):

Treatment of Asthma

2.2 Indication(s) targeted by the PIP:

Maintenance treatment of asthma in patients aged 5 years or older who have inadequately controlled asthma despite therapy with inhaled corticosteroids and long acting beta agonists.

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

The paediatric population from 5 years to less than 18 years of age

2.4 Pharmaceutical Form(s):

Inhalation powder, pre-dispensed

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	0	Not applicable.
Non-Clinical Studies	0	Not applicable.
Clinical Studies	3	Study 1 (206867) Double-blind, randomised 24-week study comparing the safety and efficacy and pharmacokinetics (PK) of fluticasone furoate (FF) / umeclidinium bromide (UMEC)/ vilanterol (VI) with FF/VI in adolescents with inadequately controlled asthma on stable maintenance therapy with inhaled corticosteroids (ICS) and long-acting # adrenoceptor agonists (LABA). Study 2 (206868) Double-blind, 3-period, 4 treatment balanced incomplete block cross-over, single-dose study to evaluate the PK and bronchodilatory effect of UMEC when added to FF/VI in children 5 years to less than 12 years of age with asthma. Study 3 (207717) Double-blind, randomised 52-week study comparing the safety and efficacy of FF / UMEC/ VI with FF/ VI in children with asthma 5 years to less than 12 years of age.
Extrapolation, Modeling & Simulation Studies	2	Study 4 Population PK models to predict the systemic exposure for each analyte in children

		and adolescents with asthma. Study 5 Physiological based pharmacokinetics (PBPK) model to predict the UMEC systemic PK following inhalation of FF/UMEC/VI in children 5 years to less than 12 years of age and to evaluate the CYP2D6 activity.
Other Studies	0	Not applicable.
Other Measures	0	Not applicable.

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	30/09/2029
Deferral of one or more studies contained in the paediatric investigation plan:	Yes